Skip Navigation



JAC Advance Access published online on November 24, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh507
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/1/31    most recent
dkh507v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Wan, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.
Right arrow Articles by Wan, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received July 1, 2004
Revised October 7, 2004
Accepted October 7, 2004

Original article

Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma

Jian Chen 1 {dagger}, Houmin Li 1 {dagger}, Ruoyu Li 1*, Dingfang Bu 1, and Zhe Wan 1

1 Department of Dermatology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, No. 8 Xishiku St, West District, Beijing, 100034, People's Republic of China

* To whom correspondence should be addressed.
Ruoyu Li, E-mail: lrywdh{at}public.bta.net.cn


  Abstract

Objectives: To monitor changes in itraconazole susceptibility of isolates from a patient undergoing treatment for pulmonary Aspergillus infection and relate these changes to genotypic/phenotypic alterations.

Methods: Six Aspergillus fumigatus isolates were serially recovered from the patient. Itraconazole MICs were determined by Etest and NCCLS methodology. Growth characteristics and phenotype were monitored. Molecular analysis included random amplified polymorphic DNA (RAPD) assay and sequencing of the cyp51A gene.

Results: The MIC of itraconazole against the first isolate before treatment was 0.25 mg/L; the MIC against the second isolate, recovered after 6 months of itraconazole therapy, was >16 mg/L; and that against the third isolate, obtained 2 months after discontinuation of the therapy, was 0.5 mg/L. The MIC against the last three isolates, acquired after restoration of itraconazole therapy for 4-7 months, was >16 mg/L. The six isolates shared identical band patterns of RAPD assay using four primers and the same sequence in intertranscribed spacers (ITS). Therefore, the six isolates were likely to be the same strain of A. fumigatus, and mutations involving itraconazole resistance possibly occurred in these isolates after prolonged itraconazole therapy. Sequencing of the cyp51A gene in the coding region revealed a mutation of M220I in cytochrome P450 sterol 14-{alpha}-demethylase in the second resistant isolate and a mutation of G54R in the last three resistant isolates. Expression changes of some pump genes, such as MDR3, may also, in part, be related to the resistance to itraconazole.

Conclusions: We conclude that resistance of A. fumigatus to itraconazole occurred in a patient treated with the drug, and the resistance may result from mutations in the cyp51A gene--the gene encoding the target enzyme for itraconazole.

Keywords: azole antifungals; resistance; genetics; MICs.

{dagger}These authors contributed equally.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, et al.
Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods
J. Clin. Microbiol., October 1, 2009; 47(10): 3142 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, P. V. Baret, M. V. Keniya, K. Tanabe, M. Niimi, A. Goffeau, and B. C. Monk
Efflux-Mediated Antifungal Drug Resistance
Clin. Microbiol. Rev., April 1, 2009; 22(2): 291 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. C. Arendrup, S. Perkhofer, S. J. Howard, G. Garcia-Effron, A. Vishukumar, D. Perlin, and C. Lass-Florl
Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus: the Challenge of Azoles versus Echinocandins
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3504 - 3511.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema
In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species
J. Clin. Microbiol., August 1, 2008; 46(8): 2568 - 2572.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. L. Rodriguez-Tudela, L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella
Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2468 - 2472.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
G. Garcia-Effron, A. Dilger, L. Alcazar-Fuoli, S. Park, E. Mellado, and D. S. Perlin
Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus
J. Clin. Microbiol., April 1, 2008; 46(4): 1200 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. L. Rodriguez-Tudela, L. Alcazar-Fuoli, A. Alastruey-Izquierdo, A. Monzon, E. Mellado, and M. Cuenca-Estrella
Time of Incubation for Antifungal Susceptibility Testing of Aspergillus fumigatus: Can MIC Values Be Obtained at 24 Hours?
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4502 - 4504.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Mellado, G. Garcia-Effron, L. Alcazar-Fuoli, W. J. G. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela
A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 1897 - 1904.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.